This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guirakhoo, F. Articles by Monath, T. Search for Related Content PubMed PubMed Citation Articles by Guirakhoo, F. Articles by Monath, T. Pubmed/NCBI databases Medline Plus Health Information Dengue

Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates

Acambis, Inc., Cambridge, Massachusetts 02139,¹ Northbrook, Illinois 60062,² Sierra Division, Discovery and Development Services, Charles River Laboratories, Inc., Sparks, Nevada 89431,³ Aventis Pasteur, Marcy-L'Etoile F-69280, France;,⁴ University of Texas Medical Branch, Galveston, Texas 77555-0609⁵

Received 17 November 2003/ Accepted 22 December 2003

To construct chimeric YF/DEN viruses (ChimeriVax-DEN), the premembrane (prM) and envelope (E) genes of yellow fever (YF) 17D virus were replaced with those of each wild-type (WT) dengue (DEN) virus representing serotypes 1 to 4. ChimeriVax-DEN1-4 vaccine viruses were prepared by electroporation of Vero cells with RNA transcripts prepared from viral cDNA (F. Guirakhoo, J. Arroyo, K. V. Pugachev, C. Miller, Z.-X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Soike, M. Ratteree, and T. P. Monath, J. Virol. 75:7290-7304, 2001; F. Guirakhoo, K. Pugachev, J. Arroyo, C. Miller, Z.-X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Draper, and T. P. Monath, Virology 298:146-159, 2002). Progeny viruses were subjected to three rounds of plaque purifications to produce the Pre-Master Seed viruses at passage 7 (P7). Three further passages were carried out using U.S. current Good Manufacturing Practices (cGMP) to produce the Vaccine Lot (P10) viruses. Preclinical studies demonstrated that the vaccine candidates are replication competent and genetically stable and do not become more neurovirulent upon 20 passages in Vero cells. The safety of a tetravalent vaccine was determined and compared to that of YF-VAX in a formal monkey neurovirulence test. Brain lesions produced by the tetravalent ChimeriVax-DEN vaccine were significantly less severe than those observed with YF-VAX. The immunogenicity and protective efficacy of four different tetravalent formulations were evaluated in cynomolgus monkeys following a single-dose subcutaneous vaccination followed by a virulent virus challenge 6 months later. All monkeys developed low levels of viremia postimmunization, and all the monkeys that had received equal concentrations of either a high-dose (5,5,5,5) or a low-dose (3,3,3,3) formulation seroconverted against all four DEN virus serotypes. Twenty-two (92%) of 24 monkeys were protected as determined by lack of viremia post-challenge. This report is the first to demonstrate the safety of a recombinant DEN virus tetravalent vaccine in a formal neurovirulence test, as well as its protective efficacy in a monkey challenge model.

This article has been cited by other articles:

• DEAUVIEAU, F., SANCHEZ, V., BALAS, C., KENNEL, A., DE MONTFORT, A., LANG, J., GUY, B. (2007). INNATE IMMUNE RESPONSES IN HUMAN DENDRITIC CELLS UPON INFECTION BY CHIMERIC YELLOW-FEVER DENGUE VACCINE SEROTYPES 1-4. Am J Trop Med Hyg 76: 144-154 [Abstract] [Full Text]  
• Chambers, T. J., Jiang, X., Droll, D. A., Liang, Y., Wold, W. S. M., Nickells, J. (2006). Chimeric Japanese encephalitis virus/dengue 2 virus infectious clone: biological properties, immunogenicity and protection against dengue encephalitis in mice.. J. Gen. Virol. 87: 3131-3140 [Abstract] [Full Text]  
• HIGGS, S., VANLANDINGHAM, D. L., KLINGLER, K. A., MCELROY, K. L., MCGEE, C. E., HARRINGTON, L., LANG, J., MONATH, T. P., GUIRAKHOO, F. (2006). GROWTH CHARACTERISTICS OF CHIMERIVAX-DEN VACCINE VIRUSES IN AEDES AEGYPTI AND AEDES ALBOPICTUS FROM THAILAND. Am J Trop Med Hyg 75: 986-993 [Abstract] [Full Text]  
• Querec, T., Bennouna, S., Alkan, S., Laouar, Y., Gorden, K., Flavell, R., Akira, S., Ahmed, R., Pulendran, B. (2006). Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203: 413-424 [Abstract] [Full Text]  
• Bonaldo, M. C., Garratt, R. C., Marchevsky, R. S., Coutinho, E. S. F., Jabor, A. V., Almeida, L. F. C., Yamamura, A. M. Y., Duarte, A. S., Oliveira, P. J., Lizeu, J. O. P., Camacho, L. A. B., Freire, M. S., Galler, R. (2005). Attenuation of Recombinant Yellow Fever 17D Viruses Expressing Foreign Protein Epitopes at the Surface. J. Virol. 79: 8602-8613 [Abstract] [Full Text]  
• Huang, C. Y.-H., Silengo, S. J., Whiteman, M. C., Kinney, R. M. (2005). Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile Virus. J. Virol. 79: 7300-7310 [Abstract] [Full Text]  
• Blaney, J. E. Jr., Matro, J. M., Murphy, B. R., Whitehead, S. S. (2005). Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a Balanced, Broad, and Protective Neutralizing Antibody Response against Each of the Four Serotypes in Rhesus Monkeys. J. Virol. 79: 5516-5528 [Abstract] [Full Text]  
• Tao, D., Barba-Spaeth, G., Rai, U., Nussenzweig, V., Rice, C. M., Nussenzweig, R. S. (2005). Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J. Exp. Med. 201: 201-209 [Abstract] [Full Text]  
• BRANDLER, S., BROWN, N., ERMAK, T. H., MITCHELL, F., PARSONS, M., ZHANG, Z., LANG, J., MONATH, T. P., GUIRAKHOO, F. (2005). REPLICATION OF CHIMERIC YELLOW FEVER VIRUS-DENGUE SEROTYPE 1-4 VIRUS VACCINE STRAINS IN DENDRITIC AND HEPATIC CELLS. Am J Trop Med Hyg 72: 74-81 [Abstract] [Full Text]  
• Goncalvez, A. P., Men, R., Wernly, C., Purcell, R. H., Lai, C.-J. (2004). Chimpanzee Fab Fragments and a Derived Humanized Immunoglobulin G1 Antibody That Efficiently Cross-Neutralize Dengue Type 1 and Type 2 Viruses. J. Virol. 78: 12910-12918 [Abstract] [Full Text]  
• Guirakhoo, F., Zhang, Z., Myers, G., Johnson, B. W., Pugachev, K., Nichols, R., Brown, N., Levenbook, I., Draper, K., Cyrek, S., Lang, J., Fournier, C., Barrere, B., Delagrave, S., Monath, T. P. (2004). A Single Amino Acid Substitution in the Envelope Protein of Chimeric Yellow Fever-Dengue 1 Vaccine Virus Reduces Neurovirulence for Suckling Mice and Viremia/Viscerotropism for Monkeys. J. Virol. 78: 9998-10008 [Abstract] [Full Text]